Found: 3
Select item for more details and to access through your institution.
BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer.
- Published in:
- Journal of Cellular Biochemistry, 2007, v. 102, n. 5, p. 1171, doi. 10.1002/jcb.21343
- By:
- Publication type:
- Article
Targeting BCL-2 overexpression in various human malignancies through NF-?B inhibition by the proteasome inhibitor bortezomib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 56, n. 1, p. 46, doi. 10.1007/s00280-004-0944-5
- By:
- Publication type:
- Article
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 54, n. 4, p. 343, doi. 10.1007/s00280-004-0811-4
- By:
- Publication type:
- Article